Assessing frailty to improve treatment for older patients with blood cancers
Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Abramson Cancer Center at Penn Medicine · NCT03680677
This study is testing if checking how frail older patients with blood cancers are can help doctors choose better treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine (other) |
| Drugs / interventions | CAR T, chemotherapy |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT03680677 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate whether frailty assessments can predict the outcomes of older patients (aged 60 and above) diagnosed with acute leukemia or myelodysplastic syndromes (MDS) after undergoing treatments such as chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplantation. By analyzing the frailty phenotype, the study seeks to optimize treatment strategies tailored to the individual needs of these patients. The research will involve collecting data on patients' health status and treatment responses to enhance decision-making in clinical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 60 years or older with a new or suspected diagnosis of acute leukemia or MDS, or those planning to undergo specific blood or marrow transplantation therapies.
Not a fit: Patients younger than 60 years or those without a hematologic malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment plans for older patients with hematologic malignancies.
How similar studies have performed: While frailty assessments in older cancer patients are being explored, this specific approach to optimize treatment strategies in hematologic malignancies is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria Arm A: * Age 60 years or older. * New diagnosis of Acute Leukemia or MDS, or suspected diagnosis. * Able to consent to the study. Eligibility Criteria Arm B: * Age 60 years or older with a hematologic malignancy. * Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy. * Able to consent to the study.
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Shannon McCurdy, MD — Abramson Cancer Center
- Study coordinator: Shannon McCurdy, MD
- Email: penncancertrials@emergingmed.com
- Phone: 855-216-0098
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Leukemia, Acute, MDS